Nextremity Earns FDA Clearance for TMT Joint System

The FDA granted Nextremity Solutions 510(k) clearance for its tarsometatarsal joint device, an addition to the InCore Lapidus system used for first tarsometatarsal fusion.

The device is indicated as a three-part construct for internal fixation for second and third tarsometatarsal infusion, also known as Lisfranc joint fusion.

The joint system, which is made up of a post and two screws, is used to improve a patient’s midfoot stability and restore the foot’s anatomical arch. The system comes with a set of accessory instruments for implant preparation and insertion.